Possible Impact of Merck Acqusition of Cubist on the Trius CVRI was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of… Trius: Will there be a Higher Bidder and what is the CVR Worth? (TSRX; $14.10)What is the CVR Worth? Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)Implications for Trius Shareholders Thoughts on the Growing Crisis of Bacterial Resistance to AntibioticsInvestment Overview SmithOnStocks Opines on Stocks May 19, EditionOne Approach for Investing in Emerging Biotechnology Stocks Trius Therapeutics: Newly Allowed Patent Provides Important New Dimension to Investment Outlook (TSRX, $8.50)Investment Thesis Trius announced an important new development today that bolsters my investment case for Trius (TSRX) and I continue with… Trius: Clinical Trials Show Important Differentiation of Tedizolid from Zyvox (TSRX, $6.48)Investment Summary and Opinion Trius: Topline Data of Second Phase III Trial of Tedizolid is Eminent (TSRX, $6.76)Investment Summary and Conclusion I began recommending Trius (TSRX) with an initiation of coverage report that was published in May of… Trius: Why Last Friday’s Equity Offering is good for the Stock (TSRX, $4.90)Investment Opinion Trius (TSRX) completed an equity offering on Friday January 19 in which it sold 6.3 million shares at $4.465.… Trius Therapeutics: In an About Face, Congress is Helping Biotech Companies That Are Developing Antibiotics (TSRX, $5.54)Investment Opinion Settlement Between Pfizer and Teva on Generic Zyvox is a Significant Positive for Trius TherapeuticsThe Issue An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)
I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report… An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)Investment Recommendation Trius Therapeutics' Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)Introduction Trius Therapeutics is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that… Trius' (TSRX) Tedizolid Has Blockbuster Potential for MRSA InfectionsTrius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that… |